epirubicin has been researched along with Disease Exacerbation in 146 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 18 (12.33) | 18.2507 |
| 2000's | 80 (54.79) | 29.6817 |
| 2010's | 46 (31.51) | 24.3611 |
| 2020's | 2 (1.37) | 2.80 |
| Authors | Studies |
|---|---|
| Barbano, R; Copetti, M; Esteller, M; Fazio, VM; Fontana, A; Graziano, P; Maiello, E; Mazza, T; Morritti, M; Murgo, R; Parrella, P; Pasculli, B; Rendina, M; Valori, VM | 1 |
| Bapat, B; Brown, J; Candrilli, SD; García-Foncillas, J; Kaye, JA; Liepa, AM; Lorenzen, S; Madhwani, S | 1 |
| Li, B; Li, C; Li, Z; Sun, S; Tu, Y; Wang, C; Wang, Z; Wu, Q; Yu, X | 1 |
| Hazama, Y; Ishida, T; Kurebayashi, J; Matsumoto, K; Matsumoto, R; Moriya, T; Murata, S; Murata, T; Nakai, Y; Nakamura, T; Nomura, T; Shimoya, K; Sugawara, S; Sugihara, M | 1 |
| Balslev, E; Bogovic, J; Brix, EH; Buhl, ASK; Christensen, IJ; Christensen, TD; Ejlertsen, B; Glavicic, V; Hansen, A; Jakobsen, EH; Jensen, PB; Knoop, AS; Knudsen, S; Langkjer, ST; Linnet, S; Luczak, A; Nelausen, KM; Nielsen, D; Rasmussen, A; Svensson, E | 1 |
| Boughey, JC; Buzdar, AU; Ellis, MJ; Hunt, KK; Leitch, AM; Meric-Bernstam, F; Royce, ME; Suman, VJ; Unzeitig, GW | 1 |
| Ali-El-Dein, B; Bazeed, MA; El-Assmy, AM; Elsawy, AA | 1 |
| Argirò, R; Bezzi, M; Catalano, C; Corona, M; Corradini, SG; Corsi, A; De Rubeis, G; Fiorentino, F; Lucatelli, P; Mennini, G; Nardis, PG; Rocco, B; Saba, L | 1 |
| Fan, W; Huang, G; Li, J; Tian, M; Zhang, X; Zhang, Y | 1 |
| Chen, J; Chen, L; Li, J; Qiu, S; Wang, Y; Yang, J; Yao, Z | 1 |
| Bae, SH; Choi, JY; Chun, HJ; Kim, HY; Lee, HG; Lee, SW; Lee, YJ; Oh, JS; Song, DS; Song, MJ; Yoon, SK | 1 |
| Bae, SH; Choi, JY; Lee, JE; Lee, MA; Yoon, SK; You, YK | 1 |
| Chen, X; Dai, H; Qian, Z; Wang, Y; Xu, X; Zhao, Y | 1 |
| Augustin, D; Böhmer, S; Du Bois, A; Erber, R; Gluz, O; Harbeck, N; Hartmann, A; Hoffmann, G; Huober, J; Jänicke, F; Kates, RE; Kiechle, M; Kreienberg, R; Kreipe, HH; Kuhn, W; Lisboa, B; Möbus, V; Mohrmann, S; Moustafa, Z; Nitz, U; Sattler, D; Scholz, M; Thomssen, C; Wallwiener, D; Weiss, E | 1 |
| Bae, SH; Cho, SB; Chung, WJ; Jang, JY; Kim, YS; Lee, SH; Park, JY; Park, SY; Song, DS; Song, MJ; Yang, JM; Yim, HJ | 1 |
| Huang, J; Li, B; Li, Q; Shen, J; Wang, J; Yuan, Y; Zheng, Y; Zou, R | 1 |
| Chen, Y; Huang, X; Liu, C; Qu, K; Qu, P; Wu, Y; Xing, J; Xu, X; Yan, Z; Yuan, P; Zhang, H; Zhang, J | 1 |
| Barlesi, F; Barre, P; Chatellain, P; Dayen, C; Derollez, M; Fournel, P; Herman, D; Jeannin, G; Lamy, PJ; Langlais, A; Lavole, A; Le Caer, H; Molinier, O; Morin, F; Moro-Sibilot, D; Mourlanette, P; Oster, JP; Pujol, JL; Quoix, E; Renault, A; Souquet, PJ; Zalcman, G | 1 |
| Dai, XL; Feng, YZ; Han, ZB; Liu, YF; Qiu, J; Yang, YT | 1 |
| Aghemo, A; Colombo, M; Crespi, S; Iavarone, M; La Mura, V; Manini, MA; Martinetti, L; Nicolini, A; Sangiovanni, A; Viganò, D | 1 |
| Ali-El-Dein, B; Babjuk, M; Birtle, A; De Nunzio, C; Gudjonsson, S; Holmang, S; Inman, BA; Kaasinen, E; N'Dow, J; Oddens, JR; Okamura, K; Oosterlinck, W; Solsona, E; Sydes, MR; Sylvester, RJ; Tatar, CA | 1 |
| Kato, T; Komiya, A; Kondo, F; Nomura, K; Wakisaka, M | 1 |
| Hashimoto, Y; Hatakeyama, S; Hosogoe, S; Imai, A; Koie, T; Mori, K; Ohyama, C; Tobisawa, Y; Yamamoto, H; Yoneyama, T | 1 |
| Ohi, H; Ozaki, T; Seki, H; Yabusaki, H | 1 |
| Advani, RH; Ansell, SM; Beaven, AW; Carson, KR; Evens, AM; Foss, F; Horwitz, S; Lechowicz, MJ; Loberiza, F; Pinter-Brown, LC; Pro, B; Savage, KJ; Shustov, AR; Smith, SM; Vose, JM | 1 |
| Benson, AB; Burtness, BA; Cohen, SJ; Douglas, K; Enzinger, PC; Goldberg, RM; Ilson, DH; Mayer, RJ; Niedzwiecki, D; Venook, A; Villaflor, VM; Ye, X | 1 |
| Hou, H; Li, T; Liu, C; Liu, D; Liu, K; Lv, H; Wang, G; Zhang, C; Zhang, X; Zhou, N; Zhu, J | 1 |
| Cui, H; Jiang, R; Li, X; Lin, X; Liu, C; Tao, R; Tian, S; Zhuang, H; Zhuo, C | 1 |
| Anthoney, A; Cheeseman, S; Collinson, M; Dent, J; Hall, PS; Howard, H; Jones, M; Last, K; Lord, SR; Lowe, C; Marshall, H; Roy, R; Seymour, MT; Swinson, D; Velikova, G | 1 |
| Goense, L; Haj Mohammad, N; Meijer, GJ; Mook, S; Ruurda, JP; van der Horst, S; van der Sluis, PC; van Hillegersberg, R; van Rossum, PSN; van Vulpen, M | 1 |
| Artal-Cortes, A; Barneto, I; Camps, C; Carrato, A; Gómez-Codina, J; González-Larriba, JL; Isla, D; Rosell, R; Safont, MJ; Sirera, R | 1 |
| Ersoy, H; Kiper, A; Sagnak, L; Topaloglu, H; Yigitbasi, O | 1 |
| Bruzzi, P; Carella, C; Conte, P; De Tursi, M; Frassoldati, A; Gennari, A; Iacobelli, S; Orlandini, C; Ricevuto, E | 1 |
| Harano, M; Higaki, K; Kagemoto, M; Kin, R; Masumura, K; Matsuura, H; Ohtani, S; Takada, S; Urashima, M | 1 |
| de la Torre-Cabrera, C; Dueñas, B; Dueñas-García, R; Fernández-Navarro, M; García-Tapiador, AM; Jaén-Morago, A; Martín-Salvago, MD; Martínez-Ortega, E; Morales, F; Ortega-Granados, AL; Ramírez-Torosa, C; Rueda, AI; Sánchez-Muñoz, A; Sánchez-Rovira, P | 1 |
| A'hern, RP; Gore, ME; Harrington, KJ; Nutting, CM; Rhys-Evans, PH; Ross, PJ; Teoh, EM | 1 |
| Arcidiacono, PG; Balzano, G; Cereda, S; Di Carlo, V; Mazza, E; Nicoletti, R; Passoni, P; Reni, M; Rognone, A; Villa, E; Zerbi, A | 1 |
| Allum, W; Ashley, S; Benson, M; Brown, G; Chau, I; Cunningham, D; Oates, J; Okines, A; Riddell, A; Starling, N; Stavridi, F; Thomas, J; Thompson, J; Wotherspoon, A | 1 |
| Blaskó, G; Nagy, Z; Turcsik, V | 1 |
| Li, J; Li, Y; Lu, M; Shen, L; Zhang, XD | 1 |
| Crisci, A; Della Melina, A; Molinara, E; Neri, B; Nicitat, G; Pantaleo, P; Rangan, S; Raugei, A; Villari, D | 1 |
| Capasso, I; Comella, G; Comella, P; D'Aiuto, G; D'Aiuto, M; Di Bonito, M; Frasci, G; Iodice, G; Lastoria, S; Montella, M; Oliviero, P; Petrillo, A; Ruffolo, P; Santangelo, M; Siani, C; Vizioli, L | 1 |
| Duchek, M; Hellsten, S; Hellström, P; Jahnson, S; Johansson, R; Malmström, PU; Mestad, O | 1 |
| Babjuk, M | 1 |
| Choi, IK; Jung, KY; Kim, CY; Kim, JS; Kim, YH; Lee, NJ; Oh, SC; Park, KH; Park, Y; Park, YJ; Seo, HY; Seo, JH; Shin, SW | 1 |
| Chen, MK; Han, H; Hou, GL; Li, YH; Liu, ZW; Lu, KS; Qin, ZK; Tu, H; Yang, ZW; Yao, K; Ye, YL; Zhang, XQ; Zhang, ZL; Zhou, FJ | 1 |
| Blohmer, JU; Friese, K; Hilfrich, J; Kleine-Tebbe, A; Koelbl, H; Kuemmel, S; Lichtenegger, W; Morack, G; Schmid, P; Sommer, H; Wischnewsky, MB | 1 |
| Chan, HH; Cheng, JT; Chien, HF; Chu, TH; Hu, TH; Kuo, HM; Lai, KH; Pan, HB; Sun, CK; Tai, MH; Wang, EM | 1 |
| Bertz, S; Danenberg, KD; Danenberg, PV; Hartmann, A; Hoffmann, AC; Lehmann, J; Leicht, C; Schuler, M; Stöckle, M; Stöhr, R; Wild, P | 1 |
| Mathew, J; Odell, JA; Stauffer, JA | 1 |
| Higashihara, H; Maeda, N; Mikami, K; Nakamura, H; Nakazawa, T; Osuga, K; Tomiyama, N; Tomoda, K | 1 |
| Barbanti, G; Bargagli, G; Chiriacò, G; Conca, R; De Rubertis, G; Fiaschi, AI; Francini, E; Francini, G; Manganelli, A; Pascucci, A; Petrioli, R; Ponchietti, R | 1 |
| Botti, G; D'Aiuto, G; De Maio, E; de Matteis, A; Di Bonito, M; Di Maio, M; Di Rella, F; Gallo, C; Gravina, A; Labonia, V; Landi, G; Morabito, A; Nuzzo, F; Pacilio, C; Perrone, F; Piccirillo, MC; Rinaldo, M; Rossi, E; Thomas, R | 1 |
| Altomare, E; Bargellini, I; Bartolozzi, C; Bertini, M; Bertoni, M; Bozzi, E; Bresci, G; Capria, A; Cicorelli, A; Cioni, R; Federici, G; Ginanni, B; Metrangolo, S; Parisi, G; Romano, A; Sacco, R; Tumino, E | 1 |
| Akiyama, F; Iwata, H; Kuroi, K; Kurosumi, M; Masuda, N; Nakamura, S; Ohashi, Y; Sato, N; Toi, M; Tsuda, H; Yamamoto, N | 1 |
| Chen, SF; Gong, C; Luo, M; Su, FX; Yao, HR; Zeng, YJ | 1 |
| Blohmer, JU; Denkert, C; Eggemann, H; Eidtmann, H; Fasching, PA; Fehm, T; Gerber, B; Hanusch, C; Hauschild, M; Huober, J; Jackisch, C; Kittel, K; Kreienberg, R; Kunz, G; Loibl, S; Müller, BM; Nekljudova, V; Rezai, M; Schrader, I; Solbach, C; Tesch, H; Untch, M; von Minckwitz, G | 1 |
| Guli, KZ; Guo, L; Hu, X; Li, X; Li, Y; Liu, W; Ma, Y; Wen, SJ; Yang, SE; Zhao, B | 1 |
| Aapro, M | 1 |
| Aström, G; Blomqvist, L; Carlsson, L; Einbeigi, Z; Fujii, H; Glimelius, B; Hatschek, T; Jacobsson, H; Linderholm, B; Lindh, B; Loman, N; Malmberg, M; Rotstein, S; Söderberg, M; Sundqvist, M; Suzuki, C; Walz, TM | 1 |
| Chan, AT; Chiu, SK; Ho, WM; Johnson, PJ; Kwan, WH; Lam, KC; Leung, TW; Mo, FK; Mok, TS; Tse, KK; Yeo, W | 1 |
| Aitini, E; Cantore, M; Guadagni, S; Rabbi, C; Zamagni, D | 1 |
| Alquati, P; Berruti, A; Bitossi, R; Bonazzi, G; Bottini, A; Bruzzi, P; Bumma, C; Castiglione, F; Danese, S; De Lena, M; De Matteis, A; DeFabiani, E; Dogliotti, L; Farris, A; Giardina, G; Gorzegno, G; Lorusso, V; Moro, G; Nuzzo, F; Sarobba, MG | 1 |
| Asola, R; Ekholm, E; Hinkka, S; Korpela, J; Mali, P; Pyrhönen, S; Salminen, E; Varjo, P; Varpula, M | 1 |
| Aapro, M; O'Shaughnessy, J; Twelves, C | 1 |
| Bonnefoi, H; Bruning, P; Cufer, T; Hamilton, A; Mauriac, L; Piccart, MJ; Pritchard, KI; Therasse, P; Tomiak, E; Welnicka-Jaskiewicz, M | 1 |
| Bengala, C; Biadi, O; Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Favre, C; Fogli, S; Guarneri, V; Innocenti, F; Mariani, M; Pazzagli, I | 1 |
| Capotorto, AM; Da Prada, GA; Farris, A; Lelli, G; Martoni, A; Massidda, B; Pavesi, L; Pedrazzoli, P; Robustelli della Cuna, G; Zamagni, C | 1 |
| Ali-El-Dein, B; Ghoneim, MA; Hinev, A; Ibrahiem, el-HI; Nabeeh, A; Sarhan, O | 1 |
| Chan, CK; Chan, LW; Chan, SF; Chan, SY; Cheng, CW; Cheung, HY; Lai, FM; Li, ML; Ng, CF; Wong, WS | 1 |
| Buda, A; Colombo, N; Conte, PF; Floriani, I; Fossati, R; Mangioni, C; Ravaioli, A; Rossi, R; Torri, V | 1 |
| Im, YH; Jung, CW; Kang, WK; Kim, HY; Kim, JH; Kim, K; Lee, MH; Lee, SH; Lee, SI; Park, J; Park, JO; Park, K; Park, YS | 1 |
| Jänicke, F; Köhler, G; Löning, T; Lück, HJ; Möbus, V; Müller, V; Pantel, K; Sattler, D; Thomssen, C; von Minckwitz, G; Wilczak, W; Witzel, I | 1 |
| Altinbas, M; Cetin, M; Coskun, HS; Er, O; Eser, B; Ozkan, M; Soyuer, S; Unal, A | 1 |
| Jassem, J; Sosińska-Mielcarek, K; Zaucha, R | 1 |
| Azarnia, N; Chan, S; Davidson, N; Erdkamp, F; Juozaityte, E; Lee, LW; Pluzanska, A | 1 |
| Besova, NS; Gorbunova, VA | 1 |
| Brausi, M; Carpentier, P; de Reijke, TM; Hall, RR; Kurth, KH; Landsoght, KE; Sylvester, RJ; van de Beek, K | 1 |
| Dörken, B; Hennesser, D; Kingreen, D; Kretzschmar, A; Micheel, S; Pink, D; Reichardt, P; Repp, M; Scholz, C; Thuss-Patience, PC | 1 |
| Abrial, C; Amat, S; Chollet, P; Delva, R; Fleury, J; Gamelin, E; Leduc, B; Penault-Llorca, F; Sillet-Bach, I; Van Praagh, I | 1 |
| Brandely, M; Coleman, R; Delozier, T; Jones, A; Kreuser, ED; Longerey, B; Mross, K; Serin, D; Verrill, M | 1 |
| Blomqvist, C; Larsson, R; Nygren, P; Villman, K | 1 |
| Albers, P; Beck, J; Becker, T; Frohneberg, D; Funke, PJ; Kälble, T; Langbein, S; Lehmann, J; Miller, K; Reiher, F; Retz, M; Roth, S; Schiller, M; Sternberg, D; Stöckle, M; Thüroff, J; Walz, P; Weining, C; Wellek, S; Wiemers, C | 1 |
| Dolezal, J; Dolezel, M; Moravek, P; Odrazka, K; Petera, J; Prosvic, P; Simakova, E; Vaculikova, M; Vosmik, M; Zoul, Z | 1 |
| Barletta, E; Bruni, GS; D'Angelo, R; Daniele, B; Ferrari, E; Fiore, F; Formato, R; Iaffaioli, RV; Ottaiano, A; Pignata, S; Tortoriello, A; Turitto, G | 1 |
| Barrett-Lee, P; Hackshaw, A; Knight, A; Leonard, R | 1 |
| André, T; Bennamoun, M; Carola, E; Flesch, M; Gamelin, E; Louvet, C; Nguyen, S; Rebischung, C; Van Ongeval, J; Ychou, M | 1 |
| Barabás, J; Cséplo, K; Németh, Z; Szabó, G; Szigeti, K; Vaszilkó, M; Velich, N | 1 |
| Bisogno, G; Casale, F; Cecchetto, G; De Salvo, G; Di Martino, M; Di Tullio, MT; Donfrancesco, A; Donofrio, V; Ferrari, A; Indolfi, P; Martone, A | 1 |
| Cheong, K; Chrystal, K; Forshaw, MJ; Gossage, JA; Harper, PG; Mason, RC | 1 |
| Aoe, K; Hiraki, A; Maeda, T; Matsuda, E; Murakami, T; Uemori, Y; Ueoka, H | 1 |
| Colleoni, M; Goldhirsch, A; Intra, M; Luini, A; Medici, M; Nolè, F; Peruzzotti, G; Renne, G; Rocca, A; Severi, G; Torrisi, R; Veronesi, P; Viale, G | 1 |
| Ah-See, ML; Beresford, MJ; Burcombe, R; Makris, A; Stott, D | 1 |
| Choi, CW; Jung, KY; Kim, BS; Kim, CY; Kim, IS; Kim, JS; Kim, SJ; Seo, HY; Seol, HR; Sung, HJ | 1 |
| Barrett-Lee, P; Grieve, R; Houston, S; Howell, A; Johnston, S; Leonard, R; Malinovszky, K; O'Reilly, S; Verrill, M; Wardley, A | 1 |
| Boidot, R; Bonnetain, F; Lizard-Nacol, S; Oudin, C; Riedinger, JM; Végran, F | 1 |
| Karakuzu, A; Koc, M; Ozdemir, S | 1 |
| Ariad, S; Bobilev, D; Geffen, DB; Tokar, M | 1 |
| Francini, E; Francini, G; Manganelli, A; Paolelli, L; Petrioli, R; Salvestrini, F | 1 |
| Bao, YH; Fang, JW; Huang, S; Mou, BH; Shen, P; Shi, MG; Xiong, PJ; Xu, N; Zhang, CX; Zhong, XL | 1 |
| Dupont, J; Jensen, BV; Jensen, HA; Pfeiffer, P | 1 |
| Audhuy, B; Bonneterre, J; Chollet, P; Clavère, P; Eymard, JC; Fargeot, P; Fumoleau, P; Goudier, MJ; Guastalla, JP; Kerbrat, P; Lortholary, A; Monnier, A; Montcuquet, P; Namer, M; Roché, H; Simon, H; Veyret, C; Walter, S | 1 |
| Bae, SH; Cho, SH; Choi, JY; Han, JY; Jang, JW; Kim, CW; Kim, DG; Lee, YS; Yang, JM; Yoon, SK | 1 |
| Bria, E; Carpino, A; Cognetti, F; Cuppone, F; Fornier, M; Nisticò, C; Pace, A; Sperduti, I; Terzoli, E | 1 |
| Adjei, AA; Aubry, MC; Delaune, R; Foster, NR; Kardinal, CG; Maurer, MJ; Nikcevich, DA; Northfelt, DW; Okuno, SH; Rowland, KM; Sloan, JA; Soori, GS | 1 |
| Calzolari, F; Cecconetto, L; Giampalma, E; Golfieri, R; Milandri, C; Passardi, A; Tison, C | 1 |
| Alvarez, A; Dirix, L; Dumez, H; Latz, J; Melemed, A; Oliveira, CT; Paridaens, R; Prové, A; Simms, L; Wildiers, H | 1 |
| Cho, JY; Choi, SH; Lee, DK; Lee, KS; Lee, SI; Lee, SJ; Lim, JY; Paik, YH; Park, HJ; Yoon, DS | 1 |
| Carpano, S; Conti, F; Di Lauro, L; Giannarelli, D; Gionfra, T; Lopez, M; Paoletti, G; Pignatti, F; Vici, P | 1 |
| Athanasiades, A; Bafaloukos, D; Bamia, C; Fountzilas, G; Giannakakis, T; Kalogera-Fountzila, A; Kosmidis, P; Pavlidis, N; Skarlos, D | 1 |
| Akesson, M; Andersson, H; Friberg, LG; Horvath, G; Johansson, O; Westberg, R | 1 |
| Bertelli, G; Bruzzi, P; Del Mastro, L; Garrone, O; Guelfi, M; Pastorino, S; Rosso, R; Sertoli, MR; Venturini, M | 1 |
| Brancaccio, L; Carnicelli, P; Cioffi, R; Comella, P; De Cataldis, G; Ianniello, GP; Lombardi, A; Maiorino, A; Scarpati, MD; Tinessa, V | 1 |
| Aravantinos, G; Beer, M; Fountzilas, G; Gennatas, K; Karpathios, S; Klouvas, G; Konstantaras, C; Kosmidis, P; Linardou, H; Makrantonakis, P; Mylonakis, N; Pavlidis, N; Skarlos, DV | 1 |
| Igawa, M; Ishibe, T; Kadena, H; Kawanishi, M; Shiina, H; Shirakawa, H; Urakami, S; Usui, T | 1 |
| Bertelsen, K; Gadeberg, CC; Havsteen, H; Jacobsen, A; Kamby, C; Sandberg, E; Sengeløv, L | 1 |
| Chao, D; Harland, SJ | 1 |
| Ali-el-Dein, B; Aly, AN; Ashamallah, A; el-Baz, M; Shamaa, S | 1 |
| Aravantinos, G; Christodoulou, C; Dimopoulos, K; Fountzilas, G; Giannakakis, T; Kastriotis, I; Kostakopoulos, CA; Linardou, E; Picramenos, D; Skarlos, DV | 1 |
| Cariello, S; Colucci, G; Galetta, D; Gebbia, N; Gebbia, V; Riccardi, F | 1 |
| Bianchi, S; Ferroni, C; Galante, E; Maymone, S; Megale, C; Molinaro, S | 1 |
| Armillotta, N; Bartolozzi, C; Cicorelli, A; Cioni, D; Di Giulio, M; Donati, F; Lencioni, R; Moretti, M; Paolicchi, A; Pinto, F | 1 |
| Andrulis, I; Blackstein, M; Franssen, E; Fraser, RA; Goss, PE; Hedley, D; Hill, W; Kates, R; Knight, S; Myers, R; Oldfield, S; Pritchard, KI; Roche, K; Trudeau, M; Warner, E; Warr, D; Webster, S | 1 |
| Ashley, S; Atra, A; Kingston, JE; Mott, M; Pinkerton, CR; Shankar, AG | 1 |
| Ardizzoia, A; Barni, S; Giani, L; Lissoni, P; Malugani, F; Mandalà, M; Paolorossi, F; Tancini, G | 1 |
| Dunst, J; Tanner, J | 1 |
| Ceresoli, GL; Dell'Oro, S; Passoni, P; Villa, E | 1 |
| Keefe, D; Kotasek, D; Marafioti, T; Norman, J; Olver, IN; Parnis, FX; Patterson, K; Russell, J; Taylor, A | 1 |
| Bauer, J; Borner, M; Crivellari, D; D'Incalci, M; Goldhirsch, A; Graffeo, R; Hess, D; Lombardi, D; Martinelli, G; Nolè, F; Pagani, O; Sessa, C; Thürlimann, B; Zucchetti, M | 1 |
| Bolis, G; Chevallier, B; Kobierska, A; Pawinski, A; Vermorken, JB; Zanaboni, F | 1 |
| Bajamonde, A; Baselga, J; Eiermann, W; Fleming, T; Fuchs, H; Leyland-Jones, B; Norton, L; Paton, V; Pegram, M; Shak, S; Slamon, DJ; Wolter, J | 1 |
| Bengala, C; Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Favre, C; Greco, F; Guarneri, V; Innocenti, F; Menconi, MC; Orlandini, C; Pazzagli, I | 1 |
| Markman, M | 1 |
| Bafaloukos, D; Briassoulis, E; Dimopoulos, AM; Fountzilas, G; Kalofonos, H; Kalogera-Fountzila, A; Keramopoulos, A; Kosmidis, P; Papadimitriou, C; Pavlidis, N; Razis, E; Samantas, E | 1 |
| Bergaglio, M; Carnino, F; Comis, S; Contu, A; Del Mastro, L; Gallo, L; Guarneri, D; Lionetto, R; Pronzato, P; Rosso, R; Venturini, M; Vesentini, L | 1 |
| Abela, K; Aravantinos, G; Bafaloukos, D; Briassoulis, E; Dafni, U; Dimopoulos, MA; Fountzilas, G; Gogas, E; Kalofonos, HP; Kosmidis, P; Moulopoulos, LA; Papadimitriou, C; Papakostas, P; Pavlidis, N; Razis, E; Skarlos, D | 1 |
| Bauer, J; Borner, M; Crivellari, D; Goldhirsch, A; Graffeo, R; Hess, D; Lombardi, D; Martinelli, G; Nolè, F; Pagani, O; Sessa, C; Thürlimann, B; Veronesi, A | 1 |
| Pagani, O; Sessa, C | 1 |
| Baselga, J | 1 |
| Carta, G; De Filippis, S; Rea, S; Recchia, F; Rosselli, M; Saggio, G | 1 |
| Evans, TR; Fullarton, GM; Garcia-Vargas, J; Harris, AL; Lofts, FJ; Mackay, HJ; McDonald, AC; McInnes, A; Paul, J; Raby, N; Soukop, M | 1 |
| Airoldi, M; Bumma, C; Cattel, L; Marchionatti, S; Pedani, F; Recalenda, V; Tagini, V | 1 |
| Amicucci, G; Deraco, M; Fiorentini, G; Guadagni, S; Miotto, D; Palumbo, G; Pilati, PL; Rossi, CR; Russo, F; Santinami, M; Valenti, M | 1 |
| Bougnoux, Ph; Eymard, JC; Lotz, V; Mansouri, H; Namer, M; Spielmann, M; Tubiana-Hulin, M; Tubiana-Mathieu, N | 1 |
| D'Agostino, G; Distefano, M; Ferrandina, G; Greggi, S; Mancuso, S; Poerio, A; Salerno, M; Scambia, G | 1 |
| Bajetta, E; Beretta, E; Bombardieri, E; Buzzoni, R; Catena, L; Celio, L; Di Bartolomeo, M; Ferrari, L; Ferrario, E; Martinetti, A; Procopio, G; Seregni, E; Vitali, M | 1 |
8 review(s) available for epirubicin and Disease Exacerbation
| Article | Year |
|---|---|
Partial hepatectomy for liver metastases from nasopharyngeal carcinoma: a comparative study and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Epirubicin; Ethiodized Oil; Female; Follow-Up Studies; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Mitomycin; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate | 2014 |
Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma
Topics: Administration, Intravesical; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Disease Progression; Doxorubicin; Epirubicin; Humans; Mitomycin; Neoplasm Recurrence, Local; Neoplasm Staging; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Thiotepa; Time Factors; Urinary Bladder Neoplasms | 2016 |
Evaluating the efficacy and safety of intravesical chemotherapies for non-muscle invasive bladder cancer: a network meta-analysis.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; BCG Vaccine; Deoxycytidine; Disease Progression; Epirubicin; Female; Gemcitabine; Humans; Isoniazid; Male; Middle Aged; Mitomycin; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Odds Ratio; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms | 2016 |
Treatment for anthracycline-pretreated metastatic breast cancer.
Topics: Administration, Oral; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Economics, Pharmaceutical; Epirubicin; Female; Fluorouracil; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK mult
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Costs and Cost Analysis; Cyclophosphamide; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Female; Filgrastim; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoadjuvant Therapy; Quality of Life; Recombinant Proteins; Survival Rate; Treatment Outcome | 2003 |
Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Disease Progression; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Randomized Controlled Trials as Topic; Regression Analysis; Survival Analysis | 2005 |
Docetaxel and epirubicin in advanced breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Epirubicin; Female; Humans; Paclitaxel; Taxoids | 2001 |
Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Humans; In Situ Hybridization, Fluorescence; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Proteins; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Retrospective Studies; Safety; Single-Blind Method; Survival Analysis; Trastuzumab; Treatment Outcome | 2001 |
88 trial(s) available for epirubicin and Disease Exacerbation
| Article | Year |
|---|---|
Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease Progression; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Progression-Free Survival; Puerto Rico; Receptor, ErbB-2; Risk Factors; Time Factors; Trastuzumab; United States | 2019 |
The value of immediate postoperative intravesical epirubicin instillation as an adjunct to standard adjuvant treatment in intermediate and high-risk non-muscle-invasive bladder cancer: A preliminary results of randomized controlled trial.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Chemotherapy, Adjuvant; Cystectomy; Cystoscopy; Disease Progression; Epirubicin; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Postoperative Care; Progression-Free Survival; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms; Young Adult | 2019 |
Comparing intra-arterial chemotherapy combined with intravesical chemotherapy versus intravesical chemotherapy alone: a randomised prospective pilot study for T1G3 bladder transitional cell carcinoma after bladder-preserving surgery.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Disease Progression; Drug Therapy, Combination; Epirubicin; Female; Follow-Up Studies; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Neoplasm Recurrence, Local; Organ Sparing Treatments; Pilot Projects; Prospective Studies; Survival Analysis; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms | 2013 |
Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease Progression; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Ki-67 Antigen; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Taxoids; Treatment Outcome; Young Adult | 2014 |
Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Cyclophosphamide; Disease Progression; Disease-Free Survival; Epirubicin; Etoposide; Female; France; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Risk Factors; Small Cell Lung Carcinoma; Time Factors; Treatment Outcome; Young Adult | 2015 |
A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.
Topics: Adult; Aged; Aged, 80 and over; Aminopterin; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Disease-Free Survival; Epirubicin; Female; Humans; Kaplan-Meier Estimate; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Prednisone; Treatment Outcome; Vincristine | 2016 |
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Disease Progression; Disease-Free Survival; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Survival Rate; Time Factors; Treatment Failure | 2016 |
A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Epirubicin; Esophageal Neoplasms; Feasibility Studies; Female; Fluorouracil; Frail Elderly; Humans; Male; Organoplatinum Compounds; Oxaliplatin; Palliative Care | 2017 |
Retrospective study of efficacy and toxicity on patients older than 70 years within a randomized clinical trial of two cisplatin-based combinations in patients with small-cell lung cancer.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Epirubicin; Etoposide; Humans; Lung Neoplasms; Middle Aged; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma; Treatment Outcome | 2009 |
Comparison of three different chemotherapy regimens containing epirubicin in hormone-refractory prostate cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Epirubicin; Humans; Male; Middle Aged; Prostatic Neoplasms; Quality of Life; Survival Analysis; Treatment Outcome | 2008 |
Epirubicin plus low-dose trastuzumab in HER2 positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Time Factors; Trastuzumab; Treatment Outcome | 2009 |
Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Disease Progression; Disease-Free Survival; Doxorubicin; Epirubicin; Female; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Middle Aged; Molecular Diagnostic Techniques; Neoadjuvant Therapy; Prognosis; Receptors, Cytoplasmic and Nuclear; Remission Induction | 2008 |
Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Therapy, Combination; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Failure; Treatment Outcome | 2009 |
A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Stomach Neoplasms; Survival Rate | 2009 |
The effect of LMWH (Nadroparin) on tumor progression.
Topics: Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Cyclophosphamide; Disease Progression; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Nadroparin; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Retrospective Studies; Survival Analysis; Time Factors | 2009 |
[Epirubicin combined with DDP and 5-Fu for treatment of advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Disease Progression; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Middle Aged; Neoplasm Staging; Neutropenia; Palliative Care; Retrospective Studies; Stomach Neoplasms; Survival Rate; Thrombocytopenia | 2009 |
Preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) improves prognosis in locally advanced breast cancer patients: an update of the Southern Italy Cooperative Oncology Group (SICOG) randomised trial 9908.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cisplatin; Combined Modality Therapy; Disease Progression; Drug Administration Schedule; Epirubicin; Etoposide; Female; Follow-Up Studies; Humans; Italy; Middle Aged; Paclitaxel; Preoperative Care; Taxoids | 2010 |
Bacillus Calmette-Guérin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study.
Topics: Administration, Intravesical; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carcinoma; Chemotherapy, Adjuvant; Cystectomy; Disease Progression; Disease-Free Survival; Epirubicin; Female; Humans; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Prospective Studies; Recombinant Proteins; Risk Assessment; Risk Factors; Scandinavian and Nordic Countries; Time Factors; Treatment Outcome; Tumor Burden; Urinary Bladder Neoplasms | 2010 |
Intra-arterial chemotherapy is reliable in preventing high-risk superficial bladder cancer from recurrence and progression.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Disease Progression; Epirubicin; Female; Humans; Infusions, Intra-Arterial; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2009 |
Epirubicin and cyclophosphamide versus epirubicin and docetaxel as first-line therapy for women with metastatic breast cancer: final results of a randomised phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Survival Rate; Taxoids; Treatment Outcome | 2010 |
MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Disease Progression; DNA-Binding Proteins; Endonucleases; Epirubicin; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Methotrexate; Middle Aged; Prognosis; Urinary Bladder Neoplasms; Vinblastine | 2010 |
Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease Progression; Docetaxel; Drug Administration Schedule; Epirubicin; Feasibility Studies; Humans; Infusions, Intravenous; Male; Middle Aged; Orchiectomy; Prednisone; Prostatic Neoplasms; Taxoids; Treatment Failure | 2011 |
Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Quality of Life; Taxoids | 2011 |
Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease Progression; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Predictive Value of Tests; Radiotherapy, Adjuvant; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Risk Factors; Taxoids; Treatment Outcome; Up-Regulation | 2011 |
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Cyclophosphamide; Disease Progression; Epirubicin; Female; Humans; Logistic Models; Mastectomy, Segmental; Medication Adherence; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Receptor, ErbB-2 | 2012 |
Impact of the first tumor response at eight weeks on overall survival in metastatic breast cancer patients treated with first-line combination chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Proportional Hazards Models; Treatment Outcome | 2013 |
Phase II study of docetaxel and epirubicin in Chinese patients with metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Progression; Docetaxel; Drug Therapy, Combination; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
Intra-arterial hepatic chemotherapy combined with continuous infusion of 5-fluorouracil in patients with metastatic cholangiocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cholangiocarcinoma; Cisplatin; Disease Progression; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Survival; Treatment Outcome | 2002 |
Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Disease Progression; Epirubicin; Female; Humans; Indazoles; Logistic Models; Middle Aged; Survival Analysis | 2002 |
Epirubicin/docetaxel regimen in progressive breast cancer-a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK mult
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Costs and Cost Analysis; Cyclophosphamide; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Female; Filgrastim; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoadjuvant Therapy; Quality of Life; Recombinant Proteins; Survival Rate; Treatment Outcome | 2003 |
Randomized, controlled, multicenter phase III trial of standard-dose fluorouracil-epirubicin-cyclophosphamide (FEC), compared with time-intensive FEC (FEC-G) and mitoxantrone-methotrexate-mitomycin C (MMM-G) in metastatic breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Disease Progression; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Survival Analysis | 2003 |
Superficial bladder tumours: analysis of prognostic factors and construction of a predictive index.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carcinoma, Transitional Cell; Disease Progression; Doxorubicin; Epirubicin; Female; Humans; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Proportional Hazards Models; Treatment Outcome; Urinary Bladder Neoplasms | 2003 |
Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the Mario Negri Institute,
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease Progression; Epirubicin; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Survival Analysis; Treatment Outcome | 2004 |
Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Docetaxel; Epirubicin; Female; Humans; Male; Middle Aged; Neutropenia; Palliative Care; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Disease Progression; Disease-Free Survival; Enzyme-Linked Immunosorbent Assay; Epirubicin; Female; Gene Expression Profiling; Humans; Immunohistochemistry; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Receptor, ErbB-2 | 2004 |
A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer.
Topics: Adult; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Dalteparin; Disease Progression; Disease-Free Survival; Epirubicin; Female; Heparin, Low-Molecular-Weight; Humans; Lung Neoplasms; Male; Middle Aged; Time Factors; Treatment Outcome; Vincristine | 2004 |
Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Doxorubicin; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Liposomes; Middle Aged; Neoplasm Metastasis; Survival Analysis; Treatment Outcome; Ventricular Dysfunction, Left | 2004 |
Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906).
Topics: Adjuvants, Immunologic; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma in Situ; Disease Progression; Epirubicin; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Multiple Primary; Survival Rate; Time Factors; Urinary Bladder Neoplasms | 2005 |
Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
Pathological and clinical response of a primary chemotherapy regimen combining vinorelbine, epirubicin, and paclitaxel as neoadjuvant treatment in patients with operable breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Drug Administration Schedule; Epirubicin; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Epirubicin; Female; Humans; Male; Methotrexate; Middle Aged; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2005 |
Second-line intra-arterial chemotherapy in advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carboplatin; Disease Progression; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Retrospective Studies; Time Factors; Treatment Outcome | 2006 |
Epirubicin-docetaxel in advanced gastric cancer: two phase II studies as second and first line treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Epirubicin; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Symptomatic responses to neoadjuvant chemotherapy for carcinoma of the oesophagus and oesophagogastric junction: are they worth measuring?
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Decision Making; Deglutition; Disease Progression; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Treatment Outcome; Weight Gain | 2006 |
Pre-treatment haemoglobin levels and the prediction of response to neoadjuvant chemotherapy in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Databases, Factual; Disease Progression; Epirubicin; Female; Fluorouracil; Hemoglobins; Humans; Menopause; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Platelet Count; Predictive Value of Tests; Prognosis; Prospective Studies; Regression Analysis; Treatment Outcome | 2006 |
TEXAS (Taxotere EXperience with Anthracyclines Study) trial: mature results of activity/toxicity of docetaxel given with anthracyclines in a community setting, as first line therapy for MBC.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Doxorubicin; Epirubicin; Female; Hospitals, Community; Humans; Middle Aged; Survival Rate; Taxoids; United Kingdom | 2007 |
Weekly docetaxel and epirubicin in treatment of advanced hormone-refractory prostate cancer.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Drug Administration Schedule; Epirubicin; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Prostatic Neoplasms; Taxoids; Treatment Failure | 2007 |
Phase II study of epirubicin plus oxaliplatin and infusional 5-fluorouracil as first-line combination therapy in patients with metastatic or advanced gastric cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Endpoint Determination; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Survival Analysis | 2007 |
Phase I study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first line therapy in patients with non-resectable gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Denmark; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Severity of Illness Index; Stomach Neoplasms; Survival Analysis; Time Factors; Treatment Outcome | 2007 |
Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Cyclophosphamide; Disease Progression; Epirubicin; Female; Fluorouracil; France; Humans; Lymphatic Metastasis; Mastectomy; Middle Aged; Survival Analysis; Vinblastine; Vinorelbine | 2007 |
Weekly epirubicin and paclitaxel with granulocyte colony-stimulating factor support in previously untreated metastatic breast cancer patients: a phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Recombinant Proteins | 2007 |
A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Injections, Intravenous; Leukopenia; Male; Mesothelioma; Middle Aged; Neutropenia; Pleural Neoplasms; Quality of Life; Remission Induction; Ribonucleotide Reductases; Survival Rate; Thrombocytopenia; Treatment Outcome | 2008 |
Intra-arterial chemotherapy of advanced pancreatic cancer: a single center experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Cancer, Regional Perfusion; Disease Progression; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Leucovorin; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2007 |
Phase I/II pharmacokinetic study of pemetrexed and epirubicin in patients with locally advanced or metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Glutamates; Guanine; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Pemetrexed; Treatment Outcome | 2007 |
Salvage chemotherapy with docetaxel and epirubicin for advanced/metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Hematologic Diseases; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Patient Selection; Platinum Compounds; Salvage Therapy; Severity of Illness Index; Stomach Neoplasms; Taxoids; Treatment Outcome | 2007 |
Intrapatient comparison of single-agent epirubicin with or without lonidamine in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Epirubicin; Female; Follow-Up Studies; Humans; Indazoles; Middle Aged; Neoplasm Metastasis; Survival Rate | 1995 |
Carboplatin in combination with epirubicin and cyclophosphamide in patients with advanced ovarian cancer. A phase II study.
Topics: Adult; Aged; Ambulatory Care; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cyclophosphamide; Disease Progression; Epirubicin; Female; Follow-Up Studies; Humans; Laparotomy; Leukopenia; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Ovarian Neoplasms; Remission Induction; Reoperation; Survival Rate; Thrombocytopenia; Vomiting | 1995 |
Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer.
Topics: Adult; Aged; Analysis of Variance; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Diethylstilbestrol; Disease Progression; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Humans; Menopause; Methotrexate; Middle Aged | 1996 |
Cisplatin, epirubicin, and vindesine with or without lonidamine in the treatment of inoperable nonsmall cell lung carcinoma: a multicenter randomized clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Epirubicin; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Vindesine | 1996 |
Carboplatin alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: a Hellenic co-operative oncology group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cyclophosphamide; Disease Progression; Disease-Free Survival; Epirubicin; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Prognosis; Prospective Studies; Remission Induction; Survival Analysis; Survival Rate | 1996 |
Intravesical instillation of epirubicin: effect on tumour recurrence in patients with dysplastic epithelium after transurethral resection of superficial bladder tumour.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Disease Progression; Disease-Free Survival; Epirubicin; Epithelium; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Risk Factors; Urinary Bladder Neoplasms | 1996 |
A phase 2 study with epirubicin as second-line treatment of patients with advanced epithelial ovarian cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Carcinoma; Disease Progression; Epirubicin; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Treatment Outcome | 1996 |
Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Chemotherapy, Adjuvant; Disease Progression; Doxorubicin; Epirubicin; Female; Humans; Male; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Urinary Bladder Neoplasms | 1997 |
Chemotherapy with methotrexate, vinblastine, epirubicin and carboplatin (Carbo-MVE) in transitional cell urothelial cancer. A Hellenic Co-Operative Oncology Group study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Combined Modality Therapy; Cystectomy; Disease Progression; Epirubicin; Female; Humans; Male; Methotrexate; Middle Aged; Treatment Outcome; Urethral Neoplasms; Urinary Bladder Neoplasms; Vinblastine; World Health Organization | 1997 |
Cisplatin and vinorelbine followed by ifosfamide plus epirubicin vs the opposite sequence in advanced unresectable stage III and metastatic stage IV non-small-cell lung cancer: a prospective randomized study of the Southern Italy Oncology Group (GOIM).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Drug Administration Schedule; Epirubicin; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prospective Studies; Vinblastine; Vinorelbine | 1997 |
Neoadjuvant treatment of cancer of the bladder with M-VAC/M-VEC, and bladder-sparing policy: preliminary report of a non-randomized study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Disease Progression; Doxorubicin; Epirubicin; Female; Humans; Male; Methotrexate; Middle Aged; Survival Analysis; Urinary Bladder Neoplasms; Vinblastine | 1996 |
Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen.
Topics: Adult; Aged; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Disease Progression; Doxorubicin; Drug Resistance, Multiple; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Verapamil | 1998 |
Chemoneuroendocrine therapy of metastatic breast cancer with persistent thrombocytopenia with weekly low-dose epirubicin plus melatonin: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Breast Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Liver Neoplasms; Lung Neoplasms; Melatonin; Middle Aged; Platelet Count; Remission Induction; Thrombocytopenia; Time Factors; Treatment Outcome | 1999 |
[Polychemotherapy versus monotherapy in metastatic breast carcinoma].
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Epirubicin; Female; Humans; Mitomycin; Neoplasm Metastasis; Quality of Life; Treatment Outcome | 1999 |
Phase II study of paclitaxel and epirubicin as first-line treatment in patients with metastatic nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Epirubicin; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Outcome; Ventricular Fibrillation | 2000 |
Phase II study of epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) for carcinoma of unknown primary site.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms, Unknown Primary; Survival Analysis; Treatment Outcome | 2000 |
Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2000 |
A phase II study of high-dose epirubicin in ovarian cancer patients previously treated with cisplatin. EORTC Gynecological Cancer Cooperative Group.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Carcinoma; Cisplatin; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Middle Aged; Ovarian Neoplasms; Treatment Outcome | 2000 |
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Doxorubicin; Epirubicin; Female; Heart Diseases; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Survival Analysis; Trastuzumab | 2001 |
High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Epirubicin; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Paclitaxel; Survival Analysis; Thiotepa; Treatment Outcome | 2001 |
Second-line therapy for potentially platinum-sensitive recurrent ovarian cancer: what is optimal treatment?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Disease-Free Survival; Epirubicin; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Randomized Controlled Trials as Topic | 2001 |
Dose-dense sequential chemotherapy with epirubicin and paclitaxel in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Confidence Intervals; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Greece; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis | 2001 |
Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter G
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2001 |
Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: a randomized study conducted by the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Treatment Outcome | 2001 |
High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Disease Progression; Docetaxel; Epirubicin; Female; Humans; Incidence; Liver Neoplasms; Middle Aged; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies; Taxoids | 2001 |
Primary chemotherapy in stage IV ovarian cancer. A prospective phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Cystadenocarcinoma; Disease Progression; Epirubicin; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Survival Rate | 2001 |
A phase II study of epirubicin, cisplatin and raltitrexed combination chemotherapy (ECT) in patients with advanced oesophageal and gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Drug Hypersensitivity; Enteritis; Epirubicin; Esophageal Neoplasms; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Pulmonary Embolism; Quinazolines; Sepsis; Stomach Neoplasms; Survival Analysis; Thiophenes; Treatment Outcome | 2001 |
Deliberate hypoxic pelvic and limb chemoperfusion in the treatment of recurrent melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Dacarbazine; Disease Progression; Disease-Free Survival; Epirubicin; Female; Hemodynamics; Humans; Hypoxia; Leg; Male; Melanoma; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Palliative Care; Pelvis; Skin Neoplasms; Treatment Outcome | 2002 |
Sequential or alternating administration of docetaxel (Taxotere) combined with FEC in metastatic breast cancer: a randomised phase II trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Neoadjuvant treatment of locally advanced carcinoma of the uterine cervix with epirubicin, paclitaxel and cisplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Disease-Free Survival; Epirubicin; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Treatment Outcome; Uterine Cervical Neoplasms | 2002 |
Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2002 |
51 other study(ies) available for epirubicin and Disease Exacerbation
| Article | Year |
|---|---|
Hsa-miR-210-3p expression in breast cancer and its putative association with worse outcome in patients treated with Docetaxel.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast; Breast Neoplasms; Cell Line, Tumor; Chemotherapy, Adjuvant; Computational Biology; Cyclophosphamide; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Epirubicin; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Mastectomy; MicroRNAs; Middle Aged; Prospective Studies; Retrospective Studies | 2019 |
Clinical management patterns of advanced and metastatic gastro-oesophageal carcinoma after fluoropyrimidine/platinum treatment in France, Germany, Spain and the United Kingdom.
Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Analgesics, Opioid; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Disease Progression; Docetaxel; Emergency Service, Hospital; Epirubicin; Esophagogastric Junction; Female; Fluorouracil; France; Germany; Guideline Adherence; Hospice Care; Hospitalization; Humans; Irinotecan; Male; Middle Aged; Nutritional Support; Oxaliplatin; Palliative Care; Practice Guidelines as Topic; Practice Patterns, Physicians'; Receptor, ErbB-2; Retrospective Studies; Spain; Stomach Neoplasms; Treatment Failure; United Kingdom | 2020 |
MEDAG enhances breast cancer progression and reduces epirubicin sensitivity through the AKT/AMPK/mTOR pathway.
Topics: AMP-Activated Protein Kinases; Animals; Antibiotics, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Disease Progression; Epirubicin; Female; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2021 |
[A Case Report of Surgery and Chemotherapy for a Patient with Rapidly Progressing Breast Cancer during Pregnancy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Disease Progression; Epirubicin; Female; Humans; Mastectomy, Radical; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic | 2018 |
Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort: a retrospective-prospective blinded study.
Topics: Adult; Aged; Biomarkers, Pharmacological; Breast Neoplasms; Disease Progression; Disease-Free Survival; Epirubicin; Female; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasm Proteins; Precision Medicine; Proportional Hazards Models; Prospective Studies; Retrospective Studies; RNA, Messenger | 2018 |
Polyethylene Glycol Epirubicin-Loaded Transcatheter Arterial Chemoembolization Procedures Utilizing a Combined Approach with 100 and 200 μm Microspheres: A Promising Alternative to Current Standards.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Biopsy; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Drug Carriers; Epirubicin; Feasibility Studies; Female; Humans; Liver Neoplasms; Male; Microspheres; Middle Aged; Particle Size; Polyethylene Glycols; Progression-Free Survival; Prospective Studies; Rome; Time Factors; Tomography, X-Ray Computed; Tumor Burden | 2019 |
Alpha-fetoprotein assessment for hepatocellular carcinoma after transarterial chemoembolization.
Topics: Adult; Aged; alpha-Fetoproteins; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Epirubicin; Ethiodized Oil; Female; Humans; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Survival Rate | 2019 |
Hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chi-Square Distribution; Cisplatin; Disease Progression; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Portal Vein; Proportional Hazards Models; Risk Factors; Time Factors; Treatment Outcome; Tumor Burden; Venous Thrombosis | 2013 |
Epirubicin, cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Disease Progression; Drug Resistance, Neoplasm; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Time Factors; Treatment Outcome | 2014 |
In vitro chemosensitivity assay of ascites in epithelial ovarian cancer.
Topics: Antineoplastic Agents; Ascites; Carboplatin; Carcinoma, Ovarian Epithelial; Coloring Agents; Deoxycytidine; Disease Progression; Drug Screening Assays, Antitumor; Epirubicin; Etoposide; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Survival Rate; Tetrazolium Salts; Thiazoles; Time Factors; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2013 |
A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Disease Progression; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Retrospective Studies; Sorafenib; Treatment Outcome; Venous Thrombosis | 2015 |
Transarterial chemoembolization aggravated peritumoral fibrosis via hypoxia-inducible factor-1α dependent pathway in hepatocellular carcinoma.
Topics: Adult; Aged; Animals; Carcinoma, Hepatocellular; Cell Hypoxia; Chemoembolization, Therapeutic; Disease Models, Animal; Disease Progression; Epirubicin; Female; Fibrosis; Fluorouracil; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Infusions, Intra-Arterial; Liver; Liver Cirrhosis, Experimental; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Rats, Sprague-Dawley | 2015 |
Efficacy and prognosis of neoadjuvant chemotherapy is correlated with breast cancer molecular classification.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Chi-Square Distribution; Disease Progression; Disease-Free Survival; Docetaxel; Epirubicin; Female; Humans; Kaplan-Meier Estimate; Neoadjuvant Therapy; Neoplasm Grading; Precision Medicine; Predictive Value of Tests; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Remission Induction; Risk Factors; Taxoids; Time Factors; Treatment Outcome | 2015 |
Transarterial chemoembolization with drug-eluting beads is effective for the maintenance of the Milan-in status in patients with a small hepatocellular carcinoma.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Decision Support Techniques; Disease Progression; Disease-Free Survival; Drug Carriers; Eligibility Determination; Epirubicin; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Liver Transplantation; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Prospective Studies; Remission Induction; Risk Factors; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden; Waiting Lists | 2015 |
Analysis of Japanese Patients Treated with or without Long-Term Epirubicin Plus Ara-C Intravesical Instillation Therapy for Low-Grade Superficial Bladder Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease Progression; Epirubicin; Female; Follow-Up Studies; Humans; Japan; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Treatment Outcome; Urinary Bladder Neoplasms | 2015 |
Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma, Transitional Cell; Combined Modality Therapy; Cystectomy; Cystoscopy; Disease Progression; Disease-Free Survival; Epirubicin; Female; Follow-Up Studies; Humans; Japan; Male; Middle Aged; Natural Orifice Endoscopic Surgery; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Retrospective Studies; Survival Rate; Treatment Outcome; Urethra; Urinary Bladder Neoplasms | 2015 |
Hepatic arterial infusion chemotherapy using fluorouracil, epirubicin, and mitomycin C for patients with liver metastases from gastric cancer after treatment failure of systemic S-1 plus cisplatin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; Cisplatin; Disease Progression; Drug Combinations; Epirubicin; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Mitomycin; Oxonic Acid; Stomach Neoplasms; Survival Rate; Tegafur; Tomography, X-Ray Computed; Treatment Failure; Treatment Outcome | 2016 |
Response to apatinib in chemotherapy-failed advanced spindle cell breast carcinoma.
Topics: Albumin-Bound Paclitaxel; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast; Carcinoma; Chemotherapy, Adjuvant; Circulating Tumor DNA; Cisplatin; Cyclophosphamide; Disease Progression; Drug Resistance, Neoplasm; Epirubicin; ErbB Receptors; Female; Hand-Foot Syndrome; High-Throughput Nucleotide Sequencing; Humans; Hypertension; Lung Neoplasms; Mastectomy, Modified Radical; Middle Aged; Mutation; Neovascularization, Pathologic; Positron Emission Tomography Computed Tomography; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sequence Analysis, DNA; Thoracic Neoplasms; Treatment Failure; Triple Negative Breast Neoplasms | 2016 |
Perioperative chemotherapy versus neoadjuvant chemoradiotherapy for esophageal or GEJ adenocarcinoma: A propensity score-matched analysis comparing toxicity, pathologic outcome, and survival.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Diarrhea; Disease Progression; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Follow-Up Studies; Humans; Leukopenia; Male; Middle Aged; Neoadjuvant Therapy; Netherlands; Paclitaxel; Propensity Score; Thromboembolism | 2017 |
[Prediction of response to primary systemic chemotherapy involving weekly paclitaxel followed by FEC 100 for advanced breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Time Factors | 2008 |
Epirubicin, cisplatin and protracted venous infusion 5-Fluorouracil chemotherapy for advanced salivary adenoid cystic carcinoma.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenoid Cystic; Cisplatin; Disease Progression; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Salivary Gland Neoplasms; Survival Analysis | 2009 |
Weekly administration of docetaxel and epirubicin as first-line treatment for hormone-refractory prostate carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Epirubicin; Humans; Male; Prostatic Neoplasms; Taxoids | 2009 |
What is the optimal treatment strategy for T1 bladder tumors?
Topics: Administration, Intravesical; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carcinoma; Cystectomy; Disease Progression; Disease-Free Survival; Epirubicin; Humans; Interferon alpha-2; Interferon-alpha; Neoplasm Recurrence, Local; Neoplasm Staging; Practice Guidelines as Topic; Recombinant Proteins; Reoperation; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Tumor Burden; Urinary Bladder Neoplasms | 2010 |
Concurrent chemoradiation followed by adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma in Korea.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Disease Progression; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Epirubicin; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lymph Nodes; Male; Middle Aged; Nasopharyngeal Neoplasms; Nasopharynx; Neoplasm Recurrence, Local; Patient Compliance; Republic of Korea; Survival Analysis; Young Adult | 2010 |
Rapid induction of orthotopic hepatocellular carcinoma in immune-competent rats by non-invasive ultrasound-guided cells implantation.
Topics: Animals; Antibiotics, Antineoplastic; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Cell Transplantation; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Epirubicin; Feasibility Studies; Immunocompetence; Liver Neoplasms; Rats; Rats, Sprague-Dawley; Ultrasonography | 2010 |
Esophageal adenocarcinoma after laparoscopic gastric band placement for obesity.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bariatric Surgery; Deglutition Disorders; Disease Progression; Epirubicin; Esophageal Neoplasms; Fatal Outcome; Fluorouracil; Gastroesophageal Reflux; Humans; Male; Obesity; Organoplatinum Compounds; Oxaliplatin | 2011 |
Transarterial chemoembolization with cisplatin as second-line treatment for hepatocellular carcinoma unresponsive to chemoembolization with epirubicin-Lipiodol emulsion.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cisplatin; Disease Progression; Emulsions; Epirubicin; Ethiodized Oil; Female; Humans; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Statistics, Nonparametric; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Transarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment: a prospective cohort study.
Topics: Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chi-Square Distribution; Disease Progression; Epirubicin; Ethiodized Oil; Female; Humans; Liver Function Tests; Liver Neoplasms; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Patient Selection; Prospective Studies; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Ubc9 expression predicts chemoresistance in breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Epirubicin; Female; Fluorouracil; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lymphatic Metastasis; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Proportional Hazards Models; Remission Induction; Tumor Burden; Ubiquitin-Conjugating Enzymes; Up-Regulation | 2011 |
[Correlation of expression of Survivin, BCRP and HER-2 genes with therapeutic response of TE regimen neoadjuvant chemotherapy in breast cancer patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Disease Progression; Docetaxel; Epirubicin; Female; Humans; Inhibitor of Apoptosis Proteins; Mastectomy, Radical; Middle Aged; Neoadjuvant Therapy; Neoplasm Proteins; Receptor, ErbB-2; Remission Induction; RNA, Messenger; Survivin; Taxoids | 2011 |
Emerging topics in anaemia and cancer.
Topics: Administration, Intravenous; Anemia, Iron-Deficiency; Antimicrobial Cationic Peptides; Disease Progression; Epirubicin; Erythrocytes; Erythroid Precursor Cells; Hematinics; Hepcidins; Humans; Iron; Meta-Analysis as Topic; Neoplasms; Quality of Life; Receptors, Erythropoietin | 2012 |
High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Daunorubicin; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Idarubicin; Melphalan; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction; Taxoids; Thiotepa; Time Factors; Transplantation Conditioning; Treatment Outcome | 2003 |
15-year experience on intravesical therapy of T1G3 urinary bladder cancer: a conservative approach.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma, Transitional Cell; Disease Progression; Doxorubicin; Epirubicin; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Proportional Hazards Models; Survival Rate; Urinary Bladder Neoplasms | 2004 |
Long-term survival of a patient with primarily chemo-resistant metastatic breast cancer treated with medroxyprogesterone acetate.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Drug Resistance, Neoplasm; Epirubicin; Female; Fluorouracil; Humans; Liver Neoplasms; Mastectomy, Modified Radical; Medroxyprogesterone Acetate; Prognosis; Treatment Outcome | 2004 |
[Role of taxanes in treatment of breast cancer].
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Data Interpretation, Statistical; Disease Progression; Docetaxel; Doxorubicin; Epirubicin; Female; Humans; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Taxoids; Time Factors; Trastuzumab | 2004 |
Predictive value of in vitro assessment of cytotoxic drug activity in advanced breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Survival; Cyclophosphamide; Disease Progression; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epirubicin; Female; Fluorometry; Fluorouracil; Humans; Methotrexate; Neoplasm Staging; Predictive Value of Tests; Prospective Studies; Quality Control; Retrospective Studies; Taxoids; Treatment Outcome; Tumor Cells, Cultured | 2005 |
Is it reasonable to consider second-line chemotherapy in patients with hormone-refractory prostate cancer?
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Hormones; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Thrombocytopenia; Time Factors; Treatment Outcome | 2005 |
[Survival prospects of mesopharyngeal carcinoma patients treated primarily with intraarterial chemotherapy. A retrospective study].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Disease Progression; Epirubicin; Female; Humans; Infusions, Intra-Arterial; Leucovorin; Male; Methotrexate; Middle Aged; Pharyngeal Neoplasms; Retrospective Studies; Survival Analysis; Treatment Outcome; Vincristine | 2006 |
Prognostic factors in pleuro-pulmonary blastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Child; Child, Preschool; Combined Modality Therapy; Dactinomycin; Disease Progression; Disease-Free Survival; Doxorubicin; Epirubicin; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Infant; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neoplasm Metastasis; Neoplasm Staging; Pleural Neoplasms; Pneumonectomy; Prognosis; Pulmonary Blastoma; Radiotherapy, Adjuvant; Retrospective Studies; Risk Factors; Second-Look Surgery; Treatment Outcome; Vincristine | 2007 |
Recurrent superior mediastinal primary hemangiopericytoma 23 years after the complete initial excision: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Epirubicin; Fatal Outcome; Hemangiopericytoma; Humans; Ifosfamide; Male; Mediastinal Neoplasms; Neoplasm Recurrence, Local; Time Factors | 2006 |
Primary therapy with ECF in combination with a GnRH analog in premenopausal women with hormone receptor-positive T2-T4 breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Disease Progression; Drug Therapy, Combination; Epirubicin; Female; Fluorouracil; Gonadotropin-Releasing Hormone; Humans; Middle Aged; Ovary; Premenopause; Treatment Outcome | 2007 |
Treatment outcome of front-line systemic chemotherapy for localized extranodal NK/T cell lymphoma in nasal and upper aerodigestive tract.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease Progression; Disease-Free Survival; Epirubicin; Female; Humans; Killer Cells, Natural; Lymphoma, T-Cell; Male; Middle Aged; Prednisone; Proportional Hazards Models; Recurrence; Remission Induction; Time Factors; Treatment Outcome; Vincristine | 2006 |
Overexpression of caspase-3s splice variant in locally advanced breast carcinoma is associated with poor response to neoadjuvant chemotherapy.
Topics: Alternative Splicing; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Carcinoma, Ductal, Breast; Caspase 3; Caspase Inhibitors; Caspases; Chemotherapy, Adjuvant; Cyclophosphamide; Disease Progression; Drug Resistance, Neoplasm; Enzyme Precursors; Epirubicin; Female; Fluorouracil; Gene Expression Regulation; Humans; Middle Aged; Neoadjuvant Therapy; Tumor Cells, Cultured | 2006 |
Multiple cutaneous metastases from male breast carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Doxorubicin; Epirubicin; Fatal Outcome; Fluorouracil; Humans; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Mastectomy, Radical; Megestrol Acetate; Middle Aged; Paclitaxel; Palliative Care; Skin Neoplasms | 2006 |
Disseminated intravascular coagulation at presentation of advanced gastric cancer.
Topics: Acute Disease; Adult; Antimetabolites, Antineoplastic; Bone Marrow Neoplasms; Cisplatin; Disease Progression; Disseminated Intravascular Coagulation; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2006 |
The best candidates for transarterial chemotherapy in patients with hepatocellular carcinoma awaiting liver transplantation: a cohort-based characterization of dropout times.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Cohort Studies; Disease Progression; Epirubicin; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Patient Dropouts; Patient Selection; Risk Factors; Waiting Lists | 2007 |
Intensive chemotherapy with high-dose epirubicin every 2 weeks and prophylactic administration of filgrastim in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Epirubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Recurrence, Local; Patient Compliance; Recombinant Proteins; Time Factors; Treatment Outcome | 1994 |
The importance of continued endocrine treatment during chemotherapy of hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diethylstilbestrol; Disease Progression; Epirubicin; Fluorouracil; Goserelin; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms | 1997 |
Combined transcatheter arterial chemoembolization and percutaneous ethanol injection for the treatment of large hepatocellular carcinoma: local therapeutic effect and long-term survival rate.
Topics: Actuarial Analysis; Aged; Antibiotics, Antineoplastic; Carcinoma, Hepatocellular; Catheterization, Peripheral; Chemoembolization, Therapeutic; Disease Progression; Epirubicin; Ethanol; Female; Follow-Up Studies; Humans; Injections, Intralesional; Liver Cirrhosis; Liver Failure; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Remission Induction; Survival Rate; Tomography, X-Ray Computed | 1998 |
A limited role for VEEP (vincristine, etoposide, epirubicin, prednisolone) chemotherapy in childhood Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cohort Studies; Disease Progression; Disease-Free Survival; Epirubicin; Etoposide; Female; Follow-Up Studies; Hodgkin Disease; Humans; Male; Prednisolone; Recurrence; Salvage Therapy; Vincristine | 1998 |
Clinical and pharmacokinetic data of a docetaxel-epirubicin combination in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Humans; Liver Neoplasms; Middle Aged; Paclitaxel; Taxoids | 2001 |